Marvin A Konstam1, Michael Kiernan2, Arthur Chandler3, Ravi Dhingra4, Freny Vaghaiwalla Mody5, Howard Eisen6, W Herbert Haught7, Lynne Wagoner8, Divya Gupta9, Richard Patten10, Paul Gordon11, Kenneth Korr11, Russell Fileccia12, Susan J Pressler13, Douglas Gregory14, Patricia Wedge14, Douglas Dowling14, Matthew Romeling14, Jeremy M Konstam14, Joseph M Massaro15, James E Udelson2. 1. Cardiovascular Center, Tufts Medical Center, Boston, Massachusetts. Electronic address: mkonstam@tuftsmedicalcenter.org. 2. Cardiovascular Center, Tufts Medical Center, Boston, Massachusetts. 3. University Cardiology Associates, Augusta, Georgia. 4. Cardiovascular Division, University of Wisconsin, Madison, Wisconsin. 5. Division of Cardiology, VA Greater Los Angeles, Los Angeles, California. 6. Division of Cardiology, Drexel University, Philadelphia, Pennsylvania. 7. Heart Center Research, Huntsville, Alabama. 8. The Heart Institute, Mercy Hospital, Fairfield, Ohio. 9. Division of Cardiology, Emory University, Atlanta, Georgia. 10. Cardiovascular Medicine, Lahey Medical Center, Burlington, Massachusetts. 11. Cardiovascular Institute, Miriam Hospital, Providence, Rhode Island. 12. Advanced Cardiovascular Specialists, Shreveport, Louisiana. 13. Center for Enhancing Quality of Life in Chronic Diseases, Indiana University School of Nursing, Indianapolis, Indiana. 14. Cardiovascular Clinical Science Foundation, Boston, Massachusetts. 15. Boston University School of Public Heath, Boston, Massachusetts.
Abstract
BACKGROUND: In patients with acute heart failure (AHF), dyspnea relief is the most immediate goal. Renal dysfunction, diuretic resistance, and hyponatremia represent treatment impediments. OBJECTIVES: It was hypothesized that the addition of tolvaptan to a background diuretic improved dyspnea early in patients selected for an enhanced vasopressin antagonism response. METHODS: In a double-blind trial, patients were randomized to tolvaptan 30 mg/day or placebo. Study entry required hospitalization within the previous 36 h, active dyspnea, and any of the following: 1) estimated glomerular filtration rate <60 ml/min/1.73 m2; 2) hyponatremia; or 3) diuretic resistance (urine output ≤125 ml/h following intravenous furosemide ≥40 mg). The primary endpoint was a 7-point change in self-assessed dyspnea at 8 and 16 h, using a novel standardized approach. RESULTS: We randomized 250 patients. There was no difference in the primary endpoint of day 1 dyspnea reduction, despite significantly greater weight reduction with tolvaptan (-2.4 ± 2.1 kg vs. -0.9 ± 1.8 kg; p < 0.001). At day 3, dyspnea reduction was greater with tolvaptan (p = 0.01). There were 2 significant treatment-by-subgroup interactions: patients without elevated jugular venous pressure and those without ascites showed directional favorability of tolvaptan over placebo for the primary endpoint compared with patients with these findings. CONCLUSIONS: Despite rapid and persistent weight loss with tolvaptan compared with placebo, in patients with AHF who were selected for greater potential benefit from vasopressin receptor inhibition, tolvaptan was not associated with greater early improvement in dyspnea. Apparent subsequent differences in dyspnea warrant further exploration of the temporal relationship between diuresis and dyspnea relief and a possible clinical role for tolvaptan. (Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management [SECRET of CHF]; NCT01584557).
RCT Entities:
BACKGROUND: In patients with acute heart failure (AHF), dyspnea relief is the most immediate goal. Renal dysfunction, diuretic resistance, and hyponatremia represent treatment impediments. OBJECTIVES: It was hypothesized that the addition of tolvaptan to a background diuretic improved dyspnea early in patients selected for an enhanced vasopressin antagonism response. METHODS: In a double-blind trial, patients were randomized to tolvaptan 30 mg/day or placebo. Study entry required hospitalization within the previous 36 h, active dyspnea, and any of the following: 1) estimated glomerular filtration rate <60 ml/min/1.73 m2; 2) hyponatremia; or 3) diuretic resistance (urine output ≤125 ml/h following intravenous furosemide ≥40 mg). The primary endpoint was a 7-point change in self-assessed dyspnea at 8 and 16 h, using a novel standardized approach. RESULTS: We randomized 250 patients. There was no difference in the primary endpoint of day 1 dyspnea reduction, despite significantly greater weight reduction with tolvaptan (-2.4 ± 2.1 kg vs. -0.9 ± 1.8 kg; p < 0.001). At day 3, dyspnea reduction was greater with tolvaptan (p = 0.01). There were 2 significant treatment-by-subgroup interactions: patients without elevated jugular venous pressure and those without ascites showed directional favorability of tolvaptan over placebo for the primary endpoint compared with patients with these findings. CONCLUSIONS: Despite rapid and persistent weight loss with tolvaptan compared with placebo, in patients with AHF who were selected for greater potential benefit from vasopressin receptor inhibition, tolvaptan was not associated with greater early improvement in dyspnea. Apparent subsequent differences in dyspnea warrant further exploration of the temporal relationship between diuresis and dyspnea relief and a possible clinical role for tolvaptan. (Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management [SECRET of CHF]; NCT01584557).
Authors: Lucas M Donovan; Peter J Rise; Shannon S Carson; Laura C Feemster; Matthew F Griffith; Vishesh K Kapur; Jerry A Krishnan; Peter K Lindenauer; Richard A Mularski; Edward T Naureckas; Brian N Palen; Elizabeth C Parsons; Laura J Spece; Michael V Vitiello; David H Au Journal: Ann Am Thorac Soc Date: 2017-12
Authors: Eva M Boorsma; Jozine M Ter Maaten; Kevin Damman; Wilfried Dinh; Finn Gustafsson; Steven Goldsmith; Daniel Burkhoff; Faiez Zannad; James E Udelson; Adriaan A Voors Journal: Nat Rev Cardiol Date: 2020-05-15 Impact factor: 32.419
Authors: Veena S Rao; Jeffrey M Turner; Matthew Griffin; Devin Mahoney; Jennifer Asher; Sangchoon Jeon; Peter S Yoo; Nabil Boutagy; Attila Feher; Albert Sinusas; F Perry Wilson; Fredric Finkelstein; Jeffrey M Testani Journal: Circulation Date: 2020-01-08 Impact factor: 29.690
Authors: Ovidiu Chioncel; Sean P Collins; Andrew P Ambrosy; Peter S Pang; Elena-Laura Antohi; Vlad Anton Iliescu; Aldo P Maggioni; Javed Butler; Alexandre Mebazaa Journal: Am J Ther Date: 2018 Jul/Aug Impact factor: 2.688